• Investor Centre

    Oventus Medical (OVN) is an ASX listed company using Airway Technology to provide innovative breathing solutions to sufferers of snoring and obstructive sleep apnoea.

     
    Market Cap:  
    Price Delay ~20min

Board and Management

Board of Directors

The Company’s Board has a broad background of executive and non-executive board experience in the health and medical device industries and early stage companies, combined with publicly listed company, capital market, financial and commercial expertise. The board comprises:  

  • Dr Mel Bridges

    Dr Mel Bridges

    Chairman and Non-Executive Director

    Mel has over 35 years’ experience founding and building international lifescience, diagnostic and medical device companies and commercialising a wide range of Australian technology. He is responsible for numerous commercial and M&A transactions and liquidity events, including listings on the ASX. Mel has received national and state business awards including the 2005 AusBiotech Chairman’s Industry Medal and 2004 Queensland Entrepreneur of the Year. Mel has founded and developed medical device and diagnostic companies, including Pacific Diagnostics (acquired by Baxter), PanBio Ltd (acquired by Inverness Medical), and ImpediMed Ltd (ASX: IPD). Mel is currently a director of ASX 100 Company ALS Ltd.  

  • Dr Chris Hart

    Dr Chris Hart

    Founder, Managing Director and Chief Executive Officer

    Chris is the founder of the Company and inventor of the O2VentTM design concept. Chris is overseeing the launch of the O2VentTM to patients and through clinicians and heads the management team as they roll out the Oventus Sleep Treatment Platform across Australia and the United States. Chris is also heavily involved with training and presenting to the dental and sleep sector. Chris graduated from the University of Queensland in 1998 with a Bachelor of Dental Science with Honours and a Bachelor of Science in Biochemistry. He has studied at Cambridge University where he graduated with a Master of Philosophy in Biomedical Science in 1999. Prior to establishing Oventus, Chris owned and managed a multi-site national dental practice, training institute and management consultancy which he sold to private equity investors. Chris also acts as an adviser to various bodies within the dental industry on the commercial aspects of health care delivery.  

  • Dr Neil Andersen

    Neil Anderson

    Chief Technical Officer

    An experienced company executive and biomaterial scientist, Neil started working with Dr Chris Hart in 2013, to develop and commercialise the O2VentTM and bring it to market. Neil has been responsible for managing the collaboration process with the CSIRO to develop a remotely-managed computer aided detection (CAD) imaging and 3D printing manufacturing platform, as well as the patent portfolio, quality systems and regulatory clearances for the product to date. Neil has 30 years’ experience in commercialising medical devices and managing the process from conception to market release including applied research, developing prototypes and testing, product development, manufacturing, regulatory submissions and clinical trials. Prior to taking on the role with Oventus, Neil founded and held the role of chief executive officer of CathRx for 10 years. In this role, Neil managed the process from the invention of the company’s technology through to commercialising a range of products leading to sales in Europe. Neil has a Bachelor of Applied Science (Hons) and a Diploma of Management and is a Graduate of the Institute of Company Directors (GAICD).  

  • Ms Sue MacLeman

    Non-Executive Director

    Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector and is currently Chair of MTPConnect (MTPII-GC Ltd), Chair of Anatara Lifesciences Ltd (ASX:ANR), Chair of Novita Healthcare Ltd (ASX:NHL), Non-Executive Director of TPI Enterprises Ltd (ASX:TPE), Non-Executive Director of Oventus Medical Ltd (ASX:OVN) and Non-Executive Director of veski. Sue is also appointed to several academic and government advisory committees.

     

  • Sharad Joshi

    Non-Executive Director

    Based in Boston, Sharad has been active in the medical technology industry for over 30 years and has held senior positions for the past 10 years including as a global entrepreneurial medical devices CEO with experience in launching medical devices, a strong track record of driving rapid global growth and laying the strategic foundations for sustained success through strategic and biomedical product innovation. Sharad brings deep expertise in the North American market in product development, marketing and sales, most recently as CEO of US headquartered Microline Surgical (a wholly owned subsidiary of Tokyo Stock Exchange listed HOYA Corporation) where he was responsible for executing growth strategy and market building, selling into 60 countries. He holds qualifications in mechanical engineering and subsequently specialised in the biomedical space and also holds an MBA.

  • Stephen Denaro

    Company Secretary

    Steve has extensive experience in mergers and acquisitions, business valuations, accountancy and income tax compliance services, as well as board corporate governance. Steve provides company secretary services for a number of biotech and software companies. Steve is also a member of the Institute of Chartered Accountants in Australia, and the Australian Institute of Company Directors.

Senior Management

 

  • Dan Parry

    Chief Financial and Operations Officer

    Dan Parry joined Oventus in December 2017 with over 20 years of experience as CFO and Company Secretary in the life science, technology and medical service sectors. Dan has held senior finance roles with companies in the US, UK and Australia, ranging from venture-backed start-ups to NASDAQ listed companies including Astellas, Synergen, Cortech, Heska, Accera and Implicit Bioscience Ltd. His experience also includes corporate finance and internal audit roles with a Fortune 100 company and six years in public accounting where Dan qualified as a CPA in the US. In these roles, Dan has managed finance, accounting, human resources, information technology, facilities, legal and compliance functions and mergers and acquisitions. Dan is professionally qualified as a Chartered Accountant in Australia and as a CPA in the US, with an MBA from the J.L. Kellogg Graduate School of Management in Chicago.

  • Robin Randolph

    Vice President Marketing and Operations, North America

    Starting her career as a nurse, then sleep technologist and clinical researcher, Robin Randolph is an accomplished marketing and sales executive with over 30 years’ experience in the sleep industry, including past ownership of US sleep centres. Robin joined Oventus Medical in April 2018 as Vice President of Marketing and Operations, North America. Robin’s vast experience spans medical device commercialisation, product management, clinical education, reimbursement and sleep centre operations management. Robin has held senior management roles in these areas for both ResMed and Fisher & Paykel Healthcare. She is passionate about education for patient management of sleep disorders, including obstructive sleep apnoea, sharing her in-depth industry knowledge and promoting the advantages of Oventus Airway Technology.